Year archive

argenx SE — 2015 filings

All 26 regulatory filings released by argenx SE (1AE) in 2015, sourced directly from the official regulator.

26 Filings

2015 Period

2015 filings (26)

Filing	Released	Lang
Interim / Quarterly Report 2015 Interim / Quarterly Report 9M 2015	2015-11-17	English
argenx Reports Third Quarter 2015 Financial Results and Provides Business Update Interim / Quarterly Report 9M 2015	2015-11-17	English
arGEN-X' Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody(TM) Against IL-6 Regulatory Filings	2015-09-23	English
arGEN-X ANNOUNCES HALF-YEAR RESULTS FOR 2015 Interim / Quarterly Report H1 2015	2015-08-26	English
Interim / Quarterly Report 2015 Interim / Quarterly Report H1 2015	2015-08-25	English
arGEN-X to Present at Wedbush PacGrow Healthcare Conference Regulatory Filings	2015-08-06	English
arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers Audit Report / Information Q3 2015	2015-07-30	English
arGEN-X N.V. announces change to the Board of Directors Board/Management Information	2015-07-16	English
arGEN-X to present at Jefferies 2015 Global Healthcare Conference on Tuesday, 2 June at 8:00 am EDT Regulatory Filings	2015-06-01	English
arGEN-X presents preliminary efficacy and expanded safety data from Phase I trial of ARGX-111 at ASCO Regulatory Filings	2015-05-29	English
arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions Capital/Financing Update	2015-05-21	English
Earnings Release 2015 Earnings Release Q1 2015	2015-05-15	English
arGEN-X Reports First Quarter 2015 Financial Results and Provides Business Update Earnings Release Q1 2015	2015-05-15	English
arGEN-X announces results of Annual General Meeting 2015 AGM Information	2015-05-13	English
arGEN-X announces publication on therapeutic potential of antibody ARGX-115 in cancer immunotherapy Regulatory Filings	2015-04-23	English
Annual Report 2014 Annual Report FY 2014	2015-04-15	English
Interim / Quarterly Report 2014 Interim / Quarterly Report 9M 2014	2015-04-15	English
arGEN-x N.V. Announces Changes to the Board of Directors Board/Management Information	2015-04-14	English
arGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111 in Patients with MET Amplified Cancers Earnings Release Q2 2015	2015-04-08	English
arGEN-X announces Annual General Meeting of Shareholders 13 May 2015 AGM Information	2015-04-01	English
arGEN-X Reports Fourth Quarter Business Update And Full Year 2014 Financial Results Earnings Release FY 2014	2015-03-18	English
arGEN-X to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference Regulatory Filings	2015-03-13	English
arGEN-X to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2014 Financial Results on March 18, 2015 Call Transcript	2015-03-11	English
arGEN-X EXPANDS PRECLINICAL PIPELINE WITH ARGX-115: A NOVEL SIMPLE ANTIBODY(TM) FOR CANCER IMMUNOTHERAPY Regulatory Filings	2015-03-04	English
Lonza and arGEN-X Announce a Multi-product GS Xceed(TM) License Agreement for Therapeutic Antibodies Capital/Financing Update	2015-02-18	English
arGEN-X Launches Innovative Access Program Regulatory Filings	2015-01-12	English

Filings by year

2026 25 filings
2025 59 filings
2024 65 filings
2023 67 filings
2022 65 filings
2021 57 filings
2020 50 filings
2019 56 filings
2018 65 filings
2017 95 filings
2016 24 filings
2015 26 filings
2014 13 filings